Angion Biomedica (NASDAQ: ANGN) will be changing to (NASDAQ: ELTX) at the open this morning. This is all a part of the merger with Elicio Therapeutics from January - with an assist from a little stock market technique to maintain the NASDAQ quotation.
Angion Biomedica is a recent-ish IPO, just over two years back. The stock's lost well over 90% of its value since the peak which presumably doesn't please shareholders. The reason for that is that at least three failures happened along the way: “Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials.” That is just the way this area of investing goes. The testing phase of the pharma business is expensive, so outside capital is needed to do it. But the entire point of testing is that some drugs and treatments will pass the tests, others won't.
Since then there's been something of a pivot, along with that merger with Elicio. The company still seems cash rich, with perhaps 8 quarters of runway. But the stock price was running at around 50 cents, $0.50. That's no good if they want to maintain the NASDAQ listing.

Angion Biomedica stock price from NASDAQ. Note this is post consolidation.
One of the customs, fashions, on the American markets is that penny stocks are regarded as being not quite respectable. Prone to manipulation perhaps. So, it's not possibly to remain on NASDAQ or NYSE with a price below the $1 minimum bid price. Angion was below this price for some months - something had to be done. As it happened the price did rise on its own, but still something was done.
That something being a reverse stock split, a consolidation. Simply declare that what used to be 10 shares, 10 pieces of paper, are now on share, one piece of paper. This doesn't change the value of the company, just the number of pieces of paper that make it up. Therefore each piece of paper rises in value - by ten times, or 1,000%, in this example.
It is, obviously, purely a nominal price change. The value of any one holding of stock doesn't change, just the number of shares in such a holding. But it achieves the goal of maintaining the NASDAQ quote, liquidity and possibly the ability to raise more capital in future. That might have a knock on effect upon valuation but stock splits can fall in value as often as rise.
The other issue is the change in the ticker, to ELTX. This will presumably be combined, at some point, with the corporate name change to Elicio. Perhaps they're hoping that we'll forget about the three failures eventually?



